The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Alifirova V.M.

Sibirskiĭ gosudarstvennyĭ meditsinskiĭ universitet, Tomsk, Russia

Boĭko A.N.

KGBUZ "Krasnoiarskiĭ kraevoĭ Tsentr po profilaktike i bor'be so SPID i infektsionnymi zabolevaniiami"

Vlasov Ia.V.

Kafedra nevrologii i neĭrokhirurgii Samarskogo gosudarstvennogo meditsinskogo universiteta

Davydovskaya M.V.

Research and Practical Centre for Clinical Investigations and Evaluation of Medical Technologies, Moscow Health Department, Moscow, Russia

Zakharova M.N.

Nauchnyĭ tsentr nevrologii RAMN, Moskva

Malkova N.A.

Novosibirskiĭ okruzhnoĭ tsentr rasseiannogo skleroza

Popova E.V.

Kafedra nervnykh bolezneĭ fakul'teta poslevuzovskogo professional'nogo obrazovaniia vracheĭ Moskovskoĭ meditsinskoĭ akademii im. I.M. Sechenova

Sivertseva S.A.

Tiumenskiĭ oblastnoĭ tsentr rasseiannogo skleroza

Spirin N.N.

Kafedra nervnykh bolezneĭ i meditsinskoĭ genetiki s kursom neĭrokhirurgii Iaroslavskoĭ gosudarstvennoĭ meditsinskoĭ akademii

Khachanova N.V.

Burdenko Neurosurgical Institute, Moscow, Russia

Shmidt T.E.

Kafedra nervnykh bolezneĭ Pervogo Moskovskogo gosudarstvennogo meditsinskogo universiteta im. I.M. Sechenova, Moskva

Clinical guidelines for the use of dimethyl fumarate in relapsing-remitting multiple sclerosis

Authors:

Alifirova V.M., Boĭko A.N., Vlasov Ia.V., Davydovskaya M.V., Zakharova M.N., Malkova N.A., Popova E.V., Sivertseva S.A., Spirin N.N., Khachanova N.V., Shmidt T.E.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(1): 97‑102

DOI: 10.17116/jnevro20171171197-102

Read: 3702 times

Download PDF (RU)
Contact the author
Table of contents

CLINICAL GUIDELINES FOR THE USE OF DIMETHYL FUMARATE IN RELAPSING-REMITTING MULTIPLE SCLEROSIS
CLINICAL GUIDELINES FOR THE USE OF DIMETHYL FUMARATE IN RELAPSING-REMITTING MULTIPLE SCLEROSIS

To cite this article:

Alifirova VM, Boĭko AN, Vlasov IaV, et al. . Clinical guidelines for the use of dimethyl fumarate in relapsing-remitting multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(1):97‑102. (In Russ.)
https://doi.org/10.17116/jnevro20171171197-102

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Clinical and epidemiological indi­cators of stroke during the COVID-19 pandemic and in the post-COVID period in the Moscow region. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12-2):5-11
Hormonal contraception methods and multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):24-30
Arte­rial hype­rtension is an oxidative stress, as a pathogenetic target for the treatment of chro­nic cere­brovascular insu­fficiency. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):84-90
Epidemiology of multiple scle­rosis in the city of Novo­sibirsk. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):119-127
Comparing the effi­cacy of divo­zilimab and second-line treatments for rela­psing-remitting multiple scle­rosis in the Russian Fede­ration: a systematic review and network meta-analysis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):58-68
Combined treatment of patients with acute muscular tonic syndrome with dorsopathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):70-77
Sleep deprivation and the deve­lopment of oxidative stress in animal models. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):124-129
Resu­lts of the All-Russian consensus conference on complications in bariatric surgery. Endo­scopic Surgery. 2025;(1):15-24
Psoriasis: analysis of como­rbid pathology. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(1):16-21
Characteristics, treatment features and in-hospital mortality of patients with myocardial infa­rction over 75 years old in Russia acco­rding to the REGION-IM regi­stry. Russian Cardiology Bulletin. 2025;(1):22-38
Abstract:

Multiple sclerosis is a chronic demyelinating and neurodegenerative disease of the central nervous system, in which autoimmune inflammation and oxidative stress play essential pathogenetic roles. Activation and infiltration of immune cells in brain tissues, lipid peroxidation products, mitochondrial dysfunction, defective antioxidant protection, and many other pathological factors result in demyelination, axonal injury and death, and apoptosis of oligodendrocytes and neurons, all of which causes constant progression of the disease. The new oral agent for the treatment of relapsing-remitting multiple sclerosis (RRMS), dimethyl fumarate (DMF), helps change the pathogenetic mechanisms of the disease, thus decreasing the rate of exacerbations, slowing down disease progression, and reducing the risk of radiological progression of the disease.

Keywords:

multiple sclerosis
oxidative stress
dimethyl fumarate

Authors:

Alifirova V.M.

Sibirskiĭ gosudarstvennyĭ meditsinskiĭ universitet, Tomsk, Russia

Boĭko A.N.

KGBUZ "Krasnoiarskiĭ kraevoĭ Tsentr po profilaktike i bor'be so SPID i infektsionnymi zabolevaniiami"

Vlasov Ia.V.

Kafedra nevrologii i neĭrokhirurgii Samarskogo gosudarstvennogo meditsinskogo universiteta

Davydovskaya M.V.

Research and Practical Centre for Clinical Investigations and Evaluation of Medical Technologies, Moscow Health Department, Moscow, Russia

Zakharova M.N.

Nauchnyĭ tsentr nevrologii RAMN, Moskva

Malkova N.A.

Novosibirskiĭ okruzhnoĭ tsentr rasseiannogo skleroza

Popova E.V.

Kafedra nervnykh bolezneĭ fakul'teta poslevuzovskogo professional'nogo obrazovaniia vracheĭ Moskovskoĭ meditsinskoĭ akademii im. I.M. Sechenova

Sivertseva S.A.

Tiumenskiĭ oblastnoĭ tsentr rasseiannogo skleroza

Spirin N.N.

Kafedra nervnykh bolezneĭ i meditsinskoĭ genetiki s kursom neĭrokhirurgii Iaroslavskoĭ gosudarstvennoĭ meditsinskoĭ akademii

Khachanova N.V.

Burdenko Neurosurgical Institute, Moscow, Russia

Shmidt T.E.

Kafedra nervnykh bolezneĭ Pervogo Moskovskogo gosudarstvennogo meditsinskogo universiteta im. I.M. Sechenova, Moskva

Close metadata

References:

  1. Lee De-H, Gold R, Linker RA. Mechanisms of Oxidative Damage in Multiple Sclerosis and Neurodegenerative Diseases: Therapeutic Modulation via Fumaric Acid Esters. Int J Mol Sci. 2012;13:11783-11803. doi:10.3390/ijms130911783
  2. Litjens NH, Burggraaf J, van Strijen E, van Gulpen C, Mattie H, Schoemaker RC, van Dissel JT, Thio HB, Nibbering PH. Pharmacokinetics of oral fumarates in healthy subjects. British Journal of Clinical Pharmacology. 2004;58(4):429-432. doi:10.1111/j.1365 -2125.2004.02145.x
  3. Mrowietz, Christophers, Altmeyer For The German Fumaric Aci. Treatment of severe psoriasis with fumaric acid esters: scientific background and guidelines for therapeutic use. British Journal of Dermatology. 1999;141(3):424-429. doi:10.1046/j.1365-2133.1999.03034.x
  4. Prosperini L, Pontecorvo S. Dimethyl fumarate in the management of multiple sclerosis: appropriate patient selection and special considerations. Therapeutics and Clinical Risk Management. 2016;12:339-350. doi:10.2147/TCRM.S85099
  5. Viglietta V, Miller D, Bar-Or A, Phillips JT, Arnold DL, Selmaj K, Kita M, Hutchinson M, Yang M, Zhang R, Dawson KT, Sheikh SI, Fox RJ, Gold R. Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials. Annals of Clinical and Translational Neurology. 2015;2(2):103-118. doi:10.1002/acn3.148
  6. Bar-Or A, Fox RJ, Gold R, Miller DH, Arnold DL, O'Gorman J, Yang M, Sheikh SI,Viglietta V, Dawson KT, Hutchinson M. Clinical and neuroradiological effect of BG-12 (dimethylfumarate) in subgroups of patients with relapsing-remitting multiple sclerosis (RRMS): an integrated analysis of the PHASE 3 DEFINE and CONFIRM studies, PND13, Value in health ( 2013) A1-A298.
  7. Gold R, Giovannoni G, Phillips JT, Fox RJ, Zhang A, Meltzer L, Kurukulasuriya NC. Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing—remitting multiple sclerosis (RRMS). Multiple Sclerosis Journal. 2015;21(1):57-66. doi:10.1177/1352458514537013
  8. Giovannoni G, Gold R, Fox RJ, Kappos L, Kita M, Yang M, Sarda SP, Zhang R, Viglietta V, Havrdova E. Relapses Requiring Intravenous Steroid Use and Multiple-Sclerosis-related Hospitalizations: Integrated Analysis of the Delayed-release Dimethyl Fumarate Phase III Studies. Clinical Therapeutics. 2015;37(11):2543-2551. doi:10.1016/j.clinthera.2015.09.011
  9. Calabresi et al. Presented at AAN; San Diego, USA; March 12-22, Oral presentation S41.005
  10. Kita M, Fox RJ, Gold R, Giovannoni G, Phillips JT, Sarda SP, Kong J, Viglietta V, Sheikh SI, Okwuokenye M, Kappos L. Effects of delayed-release dimethyl fumarate (DMF) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: an integrated analysis of the phase 3 DEFINE and CONFIRM studies. Clinical Therapeutics. 2014;36(12):1958-1971. doi:10.1016/j.clinthera.2014.08.013
  11. Selmaj K, Fox RJ, Gold R, Havrdova E et al., Safety and Tolerability of BG-12 (Dimethyl Fumarate) in Patients with Relapsing—Remitting Multiple Sclerosis: An Integrated Analysis of the Placebo-controlled Studies, presented at 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 10—13 October, 2012, Lyon, France; 484.
  12. Zurawski J, Flinn A, Sklover L, Sloane JA. Relapse frequency in transitioning from natalizumab to dimethyl fumarate: assessment of risk factors. Journal of Neurology. 2016;263(8):1511-1517. doi:10.1007/s00415-016-8162-8
  13. Theodore Phillips J, Erwin AA, Agrella S, Kremenchutzky M, Kramer JF, Darkes MJ, Kendter J, Abourjaily H, Rana J, Fox RJ. Consensus Management of Gastrointestinal Events Associated with Delayed-Release Dimethyl Fumarate: A Delphi Study. Neurology and Therapy. 2015;4(2):137-146. doi:10.1007/s40120-015-0037-x
  14. Prosperini L, Pontecorvo S. Dimethyl fumarate in the management of multiple sclerosis: appropriate patient selection and special considerations, Therapeutics and Clinical Risk Management, 2016;12:339-350. doi:10.2147/TCRM.S85099
  15. Berkovich R, Weiner L. Effects of dimethyl fumarate on lymphocyte subsets. Multiple Sclerosis and Related Disorders. 2015;4(4):339-341. doi:10.1016/j.msard.2015.06.002
  16. Longbrake E, Naismith R, Parks B, Wu G, Cross A. Dimethyl fumarate-associated lymphopenia: Risk factors and clinical significance. Multiple Sclerosis Journal — Experimental, Translational and Clinical. 2015;1(0). doi:10.1177/2055217315596994
  17. New EMA recommendations on Tecfidera. Reactions Weekly. 2015;1576(1):7. doi:10.1007/s40278-015-10164-9
  18. Gold R, Phillips JT, Havrdova E, Bar-Or A, Kappos L, Kim N, Thullen T, Valencia P, Oliva L, Novas M, Li J, Sweetser MT, Kurukulasuriya N, Viglietta V, Fox RJ. Delayed-Release Dimethyl Fumarate and Pregnancy: Preclinical Studies and Pregnancy Outcomes from Clinical Trials and Postmarketing Experience. Neurology and Therapy. 2015;4(2):93-104. doi:10.1007/s40120-015-0033-1
  19. Coyle PK. Management of women with multiple sclerosis through pregnancy and after childbirth. Therapeutic Advances in Neurological Disorders. 2016;9(3):198-210. doi:10.1177/1756285616631897
  20. Rudick RA, Polman CH. Current approaches to the identification management of breakthrough disease in patients with multiple sclerosis. Lancet Neurology. 2009;8(6):545-59. doi:10.1016/S1474-4422(09)70082-1
  21. Kappos L, Gold R, Miller DH, Macmanus DG, Havrdova E, Limmroth V, Polman CH, Schmierer K, Yousry TA, Yang M, Eraksoy M, Meluzinova E, Rektor I, Dawson KT, Sandrock AW, O'Neill GN; BG-12 Phase IIb Study Investigators. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIB study. Lancet. 2008;372(9648):1463-1472. doi:10.1016/S0140-6736(08)61619-0
  22. Prosperini L, Giannì C, Leonardi L, De Giglio L, Borriello G, Galgani S, Pozzilli C, Gasperini C. Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis. Multiple Sclerosis. 2012;18(1):64-71. doi:10.1177/1352458511417481
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.